Bristol-Myers Squibb: Lung Diseases, Interstitial trials

The registry lists 10 Lung Diseases, Interstitial studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 4Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of BMS-986553 in Participants With Refractory Autoimmune DiseasesNot yet recruitingNCT07873931Phase 1
• A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisCompletedNCT04308681Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisTerminatedNCT03142191Phase 2Results posted
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung DiseaseTerminatedNCT01559129Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisActive, not recruitingNCT06025578Phase 3
• Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CompletedNCT03098589
• A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCompletedNCT02922543
• A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCompletedNCT02921828
• A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCompletedNCT02921802
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT01203943Phase 2